IDEAS home Printed from https://ideas.repec.org/a/spr/eujhec/v23y2022i3d10.1007_s10198-021-01378-x.html
   My bibliography  Save this article

Cost-minimization analysis of immunoglobulin treatment of primary immunodeficiency diseases in Spain

Author

Listed:
  • Laia Alsina

    (Hospital Sant Joan de Déu, Universitat de Barcelona)

  • J. Bruno Montoro

    (Hospital Universitari Vall d’Hebron)

  • Pedro Moral Moral

    (Sección de Inmunopatología Y Enfermedades Minoritarias, Hospital Universitari I Politècnic La Fe)

  • Olaf Neth

    (Hospital Universitario Virgen del Rocío/Instituto de Biomedicina de Sevilla (IBiS))

  • Marta Ortiz Pica

    (Hospital Clínico San Carlos)

  • Silvia Sánchez-Ramón

    (IML, Hospital Clínico San Carlos, Universidad Complutense of Madrid)

  • María Presa

    (Pharmacoeconomics and Outcomes Research Iberia (PORIB))

  • Itziar Oyagüez

    (Pharmacoeconomics and Outcomes Research Iberia (PORIB))

  • Miguel Ángel Casado

    (Pharmacoeconomics and Outcomes Research Iberia (PORIB))

  • Luis Ignacio González-Granado

    (University Hospital 12 Octubre/Research Institute Hospital
    Complutense University)

Abstract

Primary immunodeficiency diseases (PID), which are comprised of over 400 genetic disorders, occur when a component of the immune system is diminished or dysfunctional. Patients with PID who require immunoglobulin (IG) replacement therapy receive intravenous IG (IVIG) or subcutaneous IG (SCIG), each of which provides equivalent efficacy. We developed a cost-minimization model to evaluate costs of IVIG versus SCIG from the Spanish National Healthcare System perspective. The base case modeled the annual cost per patient of IVIG and SCIG for the mean doses (per current expert clinical practice) over 1 year in terms of direct (drug and administration) and indirect (lost productivity for adults and parents/guardians of pediatric patients) costs. It was assumed that all IVIG infusions were administered in a day hospital, and 95% of SCIG infusions were administered at home. Drug costs were calculated from ex-factory prices obtained from local databases minus the mandatory deduction. Costs were valued on 2018 euros. The annual modeled costs were €4,266 lower for patients with PID who received SCIG (total €14,466) compared with those who received IVIG (total €18,732). The two largest contributors were differences in annual IG costs as a function of dosage (– €1,927) and hospital administration costs (– €2,688). However, SCIG incurred training costs for home administration (€695). Sensitivity analyses for two dose-rounding scenarios were consistent with the base case. Our model suggests that SCIG may be a cost-saving alternative to IVIG for patients with PID in Spain.

Suggested Citation

  • Laia Alsina & J. Bruno Montoro & Pedro Moral Moral & Olaf Neth & Marta Ortiz Pica & Silvia Sánchez-Ramón & María Presa & Itziar Oyagüez & Miguel Ángel Casado & Luis Ignacio González-Granado, 2022. "Cost-minimization analysis of immunoglobulin treatment of primary immunodeficiency diseases in Spain," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 23(3), pages 551-558, April.
    • Handle: RePEc:spr:eujhec:v:23:y:2022:i:3:d:10.1007_s10198-021-01378-x
    DOI: 10.1007/s10198-021-01378-x
    as

    Download full text from publisher

    File URL: http://link.springer.com/10.1007/s10198-021-01378-x
    File Function: Abstract
    Download Restriction: Access to the full text of the articles in this series is restricted.
    File URL: https://libkey.io/10.1007/s10198-021-01378-x?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    References listed on IDEAS

    as
    1. J. Beauté & Pierre Lévy & V. Millet & M. Debré & Y. Dudoit & L. Le Mignot & A. Tajahmady & C. Thomas & F. Suarez & I. Pellier & O. Hermine & N. Aladjidi & N. Mahlaoui & A. Fischer, 2010. "Economic evaluation of immunoglobulin replacement in patients with primary antibody deficiencies," Post-Print hal-01293729, HAL.
    2. repec:dau:papers:123456789/12011 is not listed on IDEAS
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Rajiv Mallick & Rashad Carlton & Joris Stiphout, 2023. "A Budget Impact Model of Maintenance Treatment of Chronic Inflammatory Demyelinating Polyneuropathy with IgPro20 (Hizentra) Relative to Intravenous Immunoglobulin in the United States," PharmacoEconomics - Open, Springer, vol. 7(2), pages 243-255, March.
    2. Clémence Perraudin & Aline Bourdin & Alex Vicino & Thierry Kuntzer & Olivier Bugnon & Jérôme Berger, 2020. "Home-based subcutaneous immunoglobulin for chronic inflammatory demyelinating polyneuropathy patients: A Swiss cost-minimization analysis," PLOS ONE, Public Library of Science, vol. 15(11), pages 1-12, November.

    More about this item

    Keywords

    Primary immunodeficiency disease; Immune system; Immunoglobulin replacement therapy; Subcutaneous immunoglobulin; Intravenous immunoglobulin; Cost-minimization analysis;
    All these keywords.

    JEL classification:

    • I11 - Health, Education, and Welfare - - Health - - - Analysis of Health Care Markets

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:eujhec:v:23:y:2022:i:3:d:10.1007_s10198-021-01378-x. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.